Advances in the diagnosis and treatment of narcolepsy-cataplexy syndrome;Avances en el diagnóstico y tratamiento del síndrome de narcolepsia-cataplejía

Revista de Neurologia

Volumn 46, Issue 9, 2008, Pages 550-556

  De Vicente Álvarez Manzaneda, Esteban E ^a,b  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b Hospital de Molina   (Spain)

Author keywords

Cataplexy; Diagnosis; Hypersomnia; Narcolepsy; Sleep; Treatment

Indexed keywords

CENTRAL STIMULANT AGENT; HLA DQ ANTIGEN; HLA DQ1 ANTIGEN; METHYLPHENIDATE; MODAFINIL; OREXIN; OXYBATE SODIUM; PROTEIN DERIVATIVE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

CATAPLEXY; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DOG; GENE MUTATION; HEREDITY; HUMAN; LABORATORY TEST; MEDICAL SPECIALIST; NARCOLEPSY; NONHUMAN; PREVALENCE; PRIMARY MEDICAL CARE; REM SLEEP; REVIEW; SLEEP DISORDER;

EID: 44449150991     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4609.2007162     Document Type: Review

References (61)

1. American Academy of Sleep Medicine. The International Classification of Sleep Disorders: diagnostic and coding manual. 2 ed. Chicago: AASM; 2005.
2. Dauvilliers Y, Billiard M, Montplaisir J. Clinical aspects and pathophysiology of narcolepsy. Clin Neurophysiol 2003; 114: 2000-17.
3. Overeem S, Mignot E, Van Dijk JG, Lammers GJ. Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol 2001; 18: 78-105.
4. Scammell TE. The neurobiology, diagnosis, and treatment of narcolepsy. Ann Neurol 2003; 53: 154-66.
5. Westphal C. Eigentümliche mit Einschlafen verbundene Anfälle. Arch Psychiatr Nervenkr 1877; 7: 631-5.
6. Gélineau J. De la narcolepsie. Gazette des Hôpitaux (Paris) 1880; 53: 626-8.
7. Yoss RE, Daly DD. On the treatment of narcolepsy. Med Clin Am 1968; 52: 781-7.
8. Ohayon MM, Priest RG, Zulley J, Smirne S, Paiva T. Prevalence of narcolepsy symptomatology and diagnosis in the European general population. Neurology 2002; 58: 1826-33.
9. Wing YK, Li RH, Lam CW, Ho CK, Fong SY, Leung T. The prevalence of narcolepsy among Chinese in Hong Kong. Ann Neurol 2002; 51: 578-84.
10. Lavie P, Peled R. Narcolepsy is a rare disease in Israel. Sleep 1987; 10: 608-9.
11. Silber MH, Krahn LE, Olson EJ, Pankratz VS. The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study. Sleep 2002; 25: 197-202.
12. Honda Y. Census of narcolepsy, cataplexy and sleep life among teenagers in Fujisawa city. Sleep Res 1979; 8: 191.
13. Dauvilliers Y, Montplaisir J, Molinari N, Carlander B, Ondze B, Besset A, et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology 2001; 57: 2029-33.
14. Orellana C, Villemin E, Tafti M, Carlander B, Besset A, Billiard M. Life events in the year preceding the onset of narcolepsy. Sleep 1994;17 (Suppl 8): S50-3.
15. Morrish E, King MA, Smith IE, Shneerson JM. Factors associated with a delay in the diagnosis of narcolepsy. Sleep Med 2004; 5: 37-41.
16. Peraita-Adrados MR. Neurobiología de la narcolepsia. Neurologia 2002; 17: 307-9.
17. Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet 2007; 369: 499-511.
18. Willie JT, Chemelli RM, Sinton CM, Tokita S, Williams SC, Kisanuki YY, et al. Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes. Neuron 2003; 38: 715-30.
19. Hara J, Beuckmann CT, Nambu T, Willie JT, Chemelli RM, Sinton CM. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 2001; 30: 345-54.
20. De Lecea L, Sutcliffe JG. The hypocretins and sleep. FEBS J 2005; 272: 5675-88.
21. Mignot E. Genetic and familial aspects of narcolepsy. Neurology 1998; 50 (Suppl 1): S16-22.
22. Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000; 27: 469-74.
23. Del Cid-Pellitero E, Garzón M. El sistema de neurotransmisión hipocretinérgico/orexinérgico en la regulación de los estados de vigilia y sueño. Rev Neurol 2007; 45: 482-90.
24. Taheri S, Mignot E. The genetics of sleep disorders. Lancet Neurol 2002; 1: 242-50.
25. Tafti M, Maret S, Dauvilliers Y. Genes for normal sleep and sleep disorders. Ann Med 2005; 37: 580-9.
26. Thorpy MJ. Cataplexy associated with narcolepsy: epidemiology, pathophysiology and management. CNS Drugs 2006; 20: 43-50.
27. Guilleminault C. Cataplexy. In Guilleminault C, Dement W, Passouant P, eds. Narcolepsy. New York: Spectrum; 1976. p. 125-43.
28. Overeem S, Reijntjes R, Huyser W, Lammers GJ, Van Dijk JG. Corticospinal excitability during laughter: implications for cataplexy and the comparison with REM sleep atonia. J Sleep Res 2004; 13: 257-64.
29. Anic-Labat S, Guilleminault C, Kraemer HC, Meehan J, Arrigoni J, Mignot E. Validation of a cataplexy questionnaire in 983 sleep disorders patients. Sleep 1999; 22: 77-87.
30. Schenck CH, Bundlie SR, Ettinger MG, Mahowald MW. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep 1986; 9: 293-308.
31. Nightingale S, Orgill JC, Ebrahim IO, De Lacy SF, Agrawal S, Williams AJ. The association between narcolepsy and REM behavior disorder (RBD). Sleep Med 2005; 6: 253-8.
32. Kotagal S, Krahn LE, Slocumb N. A putative link between childhood narcolepsy and obesity. Sleep Med 2004; 5: 147-50.
33. Roth B, Nevsimalova S. Depression in narcolepsy and hypersommia. Schweiz Arch Neurol Neurochir Psychiatr 1975; 116: 291-300.
34. Peraita-Adrados R. Avances en el estudio de los trastornos del sueño. Rev Neurol 2005; 40: 485-91.
35. Kryger MH, Walld R, Manfreda J. Diagnoses received by narcolepsy patients in the year prior to diagnosis by a sleep specialist. Sleep 2002; 25: 36-41.
36. Carskadon MA, Mitler MM, Roth T. Guidelines for the Multiple Sleep Latency Test (MSLT): a standard measure of sleepiness. Sleep 1986; 9: 519-24.
37. Dauvilliers Y, Gosselin A, Paquet J, Touchon J, Billiard M, Montplaisir J. Effect of age on MSLT results in patients with narcolepsy-cataplexy. Neurology 2004; 62: 46-50.
38. Mignot E, Lammers GJ, Ripley B, Okun M, Nevsimalova S, Overeem S, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002; 59: 1553-62.
39. Bassetti C, Gugger M, Bischof M, Mathis J, Sturzenegger C, Werth E. The narcoleptic borderland: a multimodal diagnostic approach including cerebrospinal fluid levels of hypocretin-1 (orexin A). Sleep Med 2003; 4: 7-12.
40. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998; 92: 573-85.
41. Dauvilliers Y, Baumann CR, Carlander B, Bischof M, Blatter T, Lecendreux M, et al. CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions. J Neurol Neurosurg Psychiatry 2003; 74: 1667-73.
42. Mignot E. Narcolepsy: pharmacology, pathophysiology, and genetics. In Kryger M, Roth T, Dement W, eds. Principles and practice of sleep. Philadelphia: Elsevier Saunders; 2005. p. 761-75.
43. Billiard M, Bassetti C, Dauvilliers Y, Dolenc-Groselj L, Lammers GJ, Mayer G, et al. EFNS guidelines on management of narcolepsy. Eur J Neurol 2006; 13: 1035-48.
44. Beusterien KM, Rogers AE, Walsleben JA, Emsellen HA, Reblando JA, Wang L, et al. Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep 1999; 22: 757-65.
45. Billiard M. Modafinil: pharmacology and therapeutic perspectives. Rev Neurol (Paris) 2003; 159: 122-5.
46. Gallopin T, Luppi PH, Rambert FA, Frydman A, Fort P. Effect of the wake-promoting agent modafinil on sleep-promoting neurons from the ventrolateral preoptic nucleus: an in vitro pharmacologic study. Sleep 2004; 27: 19-25.
47. Standards of Practice Committee of the American Sleep Disorders Association. Practice parameters for the use of stimulants in the treatment of narcolepsy. Sleep 1994; 17: 348-51.
48. Standards of Practice Committee. Practice parameters for the treatment of narcolepsy: an update for 2000. Sleep 2001; 24: 451-66.
49. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurology 1998; 43: 88-97.
50. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology 2000; 54: 1166-75.
51. Houghton WC, Scammell TE, Thorpy M. Pharmacotherapy for cataplexy. Sleep Med Rev 2004; 8: 355-66.
52. Black J, Houghton W, Xyrem International Study Group. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep 2006; 29: 939-46.
53. US Xyrem Multicenter Study Group. A randomized, double-blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002; 25: 42-9.
54. US Xyrem Multicenter Study Group. A 12-month, open-label multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 2003; 26: 31-5.
55. Xyrem International Study Group. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med 2005; 1: 391-7.
56. US Xyrem Multicenter Study Group. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med 2004; 5: 119-23.
57. Xyrem International Study Group. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients. Sleep Med 2005; 6: 415-21.
58. Daniels E, King MA, Smith IE, Shneerson JM. Health-related quality of life in narcolepsy. J Sleep Res 2001; 10: 75-81.
59. Findley L, Unverzagt M, Guchu R, Fabrizio M, Buckner J, Suratt P. Vigilance and automobile accidents in patients with sleep apnoea or narcolepsy. Chest 1995; 108: 619-24.
60. Martínez-Salcedo E, Lloret-Sempere T, García-Navarro M, Sellés-Galiana MF. Narcolepsia en niños. Rev Neurol 2001; 33: 1049-53.
61. León-Muñoz L, De la Calzada MD, Guitart M. Prevalencia de accidentes en un grupo de pacientes afectos de síndrome de narcolepsia-cataplejía. Rev Neurol 2000; 30: 596-8.